Edwards Lifesciences (NYSE:EW) issued an update on its FY19 earnings guidance on Thursday morning. The company provided EPS guidance of $5.05-5.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.19. The company issued revenue guidance of $3.9-4.3 billion, compared to the consensus revenue estimate of $4.16 billion.Edwards Lifesciences also updated its FY18 guidance to $4.60-4.75 EPS.

NYSE:EW traded up $1.72 on Thursday, hitting $159.07. The stock had a trading volume of 1,149,523 shares, compared to its average volume of 1,340,358. The stock has a market capitalization of $32.89 billion, a price-to-earnings ratio of 41.86, a PEG ratio of 2.07 and a beta of 0.90. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.85 and a current ratio of 2.31. Edwards Lifesciences has a 52-week low of $110.68 and a 52-week high of $175.00.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, October 23rd. The medical research company reported $1.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.05. The business had revenue of $906.60 million for the quarter, compared to analysts’ expectations of $927.56 million. Edwards Lifesciences had a return on equity of 30.11% and a net margin of 20.67%. The business’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same period last year, the firm posted $0.84 earnings per share. As a group, equities analysts forecast that Edwards Lifesciences will post 4.7 earnings per share for the current fiscal year.

EW has been the topic of several research reports. SunTrust Banks raised their target price on Edwards Lifesciences to $200.00 and gave the stock a buy rating in a research report on Friday, September 28th. Zacks Investment Research raised Edwards Lifesciences from a hold rating to a buy rating and set a $185.00 target price on the stock in a research report on Wednesday, September 26th. ValuEngine raised Edwards Lifesciences from a hold rating to a buy rating in a research report on Wednesday, September 19th. Cowen set a $190.00 target price on Edwards Lifesciences and gave the stock a buy rating in a research report on Friday, November 30th. Finally, Jefferies Financial Group raised their target price on Edwards Lifesciences from $168.00 to $180.00 and gave the stock a buy rating in a research report on Thursday. Two analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have given a buy rating to the stock. The company has an average rating of Buy and a consensus target price of $161.70.

In other news, VP Huimin Wang sold 33,800 shares of Edwards Lifesciences stock in a transaction dated Tuesday, November 6th. The stock was sold at an average price of $150.43, for a total transaction of $5,084,534.00. Following the transaction, the vice president now directly owns 81,665 shares of the company’s stock, valued at approximately $12,284,865.95. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 5,500 shares of Edwards Lifesciences stock in a transaction dated Wednesday, September 12th. The shares were sold at an average price of $144.16, for a total value of $792,880.00. Following the transaction, the vice president now directly owns 25,490 shares in the company, valued at $3,674,638.40. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 183,356 shares of company stock worth $27,011,207. Insiders own 1.84% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Edwards Lifesciences (EW) Issues FY19 Earnings Guidance” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/edwards-lifesciences-ew-issues-fy19-earnings-guidance/2664888.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

See Also: Ex-Dividend

Earnings History and Estimates for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.